Related Experiment Video

Updated: Aug 8, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

Role of itraconazole in haematology/oncology

N A Pandya1, A A Atra, U Riley

  • 1Department of Paediatric Oncology, The Royal Marsden Hospital NHS Trust, Institute of Cancer Research, Sutton, Surrey SM2 5PT, UK.

Archives of Disease in Childhood
|February 25, 2003
PubMed

Insights

Itraconazole is a key antifungal medication for children undergoing cancer treatment. Its broad effectiveness and flexible dosing options aid in managing fungal infections in this vulnerable group.

Area of Science:

  • Medical Mycology
  • Paediatric Haematology
  • Clinical Oncology

Background:

  • Fungal infections pose a significant risk to immunocompromised patients, particularly those in paediatric haematology/oncology.
  • Amphotericin B and azoles (fluconazole, itraconazole, voriconazole) are primary antifungal agents for prophylaxis and treatment.
  • Itraconazole offers a broad spectrum of activity against various fungi.

Purpose of the Study:

  • To review the specific role and application of itraconazole in paediatric haematology/oncology.
  • To evaluate the clinical utility of itraconazole in managing fungal infections in paediatric cancer patients.

Main Methods:

  • Literature review of studies on itraconazole use in paediatric haematology/oncology.
  • Analysis of antifungal spectrum, pharmacokinetics, and clinical outcomes associated with itraconazole.
  • Assessment of oral and intravenous formulations for treatment flexibility.

Main Results:

  • Itraconazole demonstrates broad-spectrum antifungal activity relevant to infections in this patient population.
  • Availability in both oral and intravenous forms enhances treatment flexibility and patient management.
  • Itraconazole provides a viable therapeutic option for paediatric patients with haematological malignancies and fungal infections.

Conclusions:

  • Itraconazole is a valuable antifungal agent in paediatric haematology/oncology practice.
  • Its efficacy and formulation flexibility support its role in the management of invasive fungal infections.
  • Further research may elucidate optimal dosing and long-term outcomes in paediatric populations.

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...